Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)

SHE:002581 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	242.82	220.25	506.4	151.91	183.8	187.8
Trading Asset Securities	0.02	0.02	-	-	-	-
Cash & Short-Term Investments	242.84	220.27	506.4	151.91	183.8	187.8
Cash Growth	-46.75%	-56.50%	233.35%	-17.35%	-2.13%	-33.91%
Accounts Receivable	209.53	279.66	93.32	172.62	179.72	272.96
Other Receivables	9.44	12.07	52.24	78.87	18.36	13.49
Receivables	218.97	291.74	145.55	251.49	198.09	286.45
Inventory	134.51	93.25	79.64	85.31	80.04	64.33
Other Current Assets	32.48	24.08	15.41	7.99	56.43	29.88
Total Current Assets	628.8	629.34	747.01	496.71	518.36	568.45
Property, Plant & Equipment	348.77	349.95	274.74	357.84	705.47	713.76
Long-Term Investments	798.27	938.34	1,056	1,355	1,503	1,223
Other Intangible Assets	87.18	90.81	93.47	108.29	126.32	134.29
Long-Term Deferred Tax Assets	29.17	27.32	11.21	6.12	11.84	25.28
Long-Term Deferred Charges	28.95	9.73	0.32	1.41	5.2	7.78
Other Long-Term Assets	124.17	122.88	13.44	12.26	0.49	83.36
Total Assets	2,045	2,168	2,196	2,337	2,870	2,756

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	72	88.39	35.35	73.69	43.64	42.13
Accrued Expenses	5.3	39.24	20.83	22.5	19.32	31.01
Short-Term Debt	36.53	32.53	2.77	13.84	150.42	151.54
Current Portion of Long-Term Debt	1.07	16.88	-	-	-	-
Current Portion of Leases	-	0.83	0.17	-	13.46	15.83
Current Income Taxes Payable	2.35	0.25	-	0.95	1.2	0.44
Current Unearned Revenue	2.86	2.99	10.46	3.59	26.86	3.43
Other Current Liabilities	15.32	9.66	13.03	19.03	109.38	14.17
Total Current Liabilities	135.43	190.78	82.61	133.61	364.28	258.54
Long-Term Debt	18.3	8.5	-	-	-	-
Long-Term Leases	2.26	2.69	-	0.71	1.47	9.8
Long-Term Unearned Revenue	5.49	5.49	5.49	5.49	6.71	9.74
Long-Term Deferred Tax Liabilities	9.67	9.59	9.39	7.51	7.68	8.68
Other Long-Term Liabilities	4.92	4.94	76.12	16.09	9.67	-
Total Liabilities	176.06	222	173.61	163.41	389.82	286.76

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	229.15	229.15	229.15	229.15	229.15	229.15
Additional Paid-In Capital	928.95	901.28	866.41	873.93	858.5	858.29
Retained Earnings	616.33	711.79	828.08	965.39	1,298	1,301
Total Common Equity	1,774	1,842	1,924	2,068	2,385	2,388
Minority Interest	94.83	104.16	98.67	105.26	94.94	81.11
Shareholders' Equity	1,869	1,946	2,022	2,174	2,480	2,469
Total Liabilities & Equity	2,045	2,168	2,196	2,337	2,870	2,756

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	58.15	61.43	2.94	14.55	165.35	177.16
Net Cash (Debt)	184.68	158.84	503.47	137.36	18.45	10.64
Net Cash Growth	-59.15%	-68.45%	266.52%	644.38%	73.50%	-90.91%
Net Cash Per Share	0.28	0.24	0.76	0.21	0.03	0.02
Filing Date Shares Outstanding	659.82	659.74	659.74	659.74	659.74	659.74
Total Common Shares Outstanding	659.82	659.74	659.74	659.74	659.74	659.74
Working Capital	493.38	438.56	664.4	363.1	154.08	309.91
Book Value Per Share	2.69	2.79	2.92	3.14	3.62	3.62
Tangible Book Value	1,687	1,751	1,830	1,960	2,259	2,254
Tangible Book Value Per Share	2.56	2.65	2.77	2.97	3.42	3.42
Buildings	-	440.69	393.55	486.08	639.62	612.92
Machinery	-	423.85	431.4	432.25	413.16	424.47
Construction In Progress	-	104.46	38.11	22.17	91.43	64.86

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 9, 2026

Data Sources Report a data error